A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan

Trial Details

NCT ID
NCT04657068
Phase
PHASE1 / PHASE2
Sponsor
Artios Pharma Ltd
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ART0380
  • Gemcitabine
  • Irinotecan
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847

Key Eligibility Criteria

  • Signed informed consent
  • Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of…
  • If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approv…
  • At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiolo…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →